Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, N.O. 111, Dade Road, Guangzhou, 510120, Guangdong Province, China.
Cancer Immunol Immunother. 2013 Oct;62(10):1629-35. doi: 10.1007/s00262-013-1465-z. Epub 2013 Aug 23.
To assess the activity and safety of postoperative adjuvant immunotherapy with transfusion of cytokine-induced killer (CIK) cells combined with chemotherapy in patients with colorectal cancer.
We retrospectively studied 96 consecutive patients with colorectal cancer who were treated with resection between January 2010 and December 2012 as well as adjuvant chemotherapy. Twenty-one of these patients accepted at least 1 cycle of CIK cell transfusion for immunotherapy (CIK group). Disease free survival (DFS), immune cells and treatment related side effects were assessed. The patients were followed up until May 2013.
By the end of follow-up, 10 patients (10.42 %) had died. Eighteen patients (18.75 %) had withdrawn. All the patients in the CIK group are still alive, and only 1 patient had withdrawn. Patients in the CIK group had significantly longer DFS than those in the control group [HR = 0.28, 95 % CI (0.09, 0.91), p = 0.034]. The 2-year DFS rates of patients in the CIK group and the control group were 59.65 ± 24.80 % and 29.35 ± 6.39 %, respectively. The CD4(+)/CD8(+) ratios were significantly lower during the period of chemotherapy than those before chemotherapy (p = 0.0038), while the ratios were significantly higher during the period of CIK cell transfusion than those before CIK therapy (p = 0.0484). There were no immediate adverse reactions to the CIK cell transfusions.
Adjuvant transfusion of CIK cells prolongs DFS in patients with colorectal cancer.
评估细胞因子诱导的杀伤（CIK）细胞输注联合化疗用于结直肠癌患者术后辅助免疫治疗的活性和安全性。
我们回顾性研究了 96 例 2010 年 1 月至 2012 年 12 月接受切除术和辅助化疗的连续结直肠癌患者。其中 21 例接受了至少 1 周期的 CIK 细胞输注免疫治疗（CIK 组）。评估无病生存期（DFS）、免疫细胞和治疗相关副作用。患者随访至 2013 年 5 月。
随访结束时，10 例（10.42%）患者死亡。18 例（18.75%）患者退出。CIK 组所有患者均存活，仅 1 例退出。CIK 组患者的 DFS 明显长于对照组[HR=0.28，95%CI（0.09，0.91），p=0.034]。CIK 组和对照组患者的 2 年 DFS 率分别为 59.65±24.80%和 29.35±6.39%。化疗期间 CD4+/CD8+比值明显低于化疗前（p=0.0038），而 CIK 细胞输注期间比值明显高于 CIK 治疗前（p=0.0484）。CIK 细胞输注无即刻不良反应。
辅助输注 CIK 细胞可延长结直肠癌患者的 DFS。
